Increased RBP4 in a human model of activated anti-atherosclerotic and antiremodelling defences

European Journal of Clinical Investigation

Volumn 44, Issue 6, 2014, Pages 567-572

  Calò, Lorenzo A ^a   Maiolino, Giuseppe ^a   Pagnin, Elisa ^a   Vertolli, Ugo ^a   Davis, Paul A ^b  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Atherosclerosis; Cardiovascular risk; HO 1; Nitric oxide; RBP4; Vascular homeostasis

Indexed keywords

ANGIOTENSIN II; HEME OXYGENASE 1; NITRIC OXIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RETINOL BINDING PROTEIN 4; HMOX1 PROTEIN, HUMAN; PLASMA RETINOL BINDING PROTEIN; RBP4 PROTEIN, HUMAN; SLC12A3 PROTEIN, HUMAN; SODIUM CHLORIDE COTRANSPORTER;

ADULT; ARTICLE; ATHEROSCLEROSIS; BARTTER SYNDROME; CARDIAC PATIENT; CARDIOVASCULAR RISK; CLINICAL ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; GITELMAN SYNDROME; HUMAN; MALE; MIDDLE AGED; MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SIGNAL TRANSDUCTION; ARTERIOSCLEROSIS; BIOLOGICAL MODEL; CASE CONTROL STUDY; GENETICS; HOMEOSTASIS; METABOLISM; MUTATION; PATHOPHYSIOLOGY; PHYSIOLOGY; RISK FACTOR; VASCULAR REMODELING; VASODILATATION;

ADULT; ARTERIOSCLEROSIS; BARTTER SYNDROME; CASE-CONTROL STUDIES; FEMALE; GITELMAN SYNDROME; HEME OXYGENASE-1; HOMEOSTASIS; HUMANS; MIDDLE AGED; MODELS, CARDIOVASCULAR; MUTATION; NITRIC OXIDE; RETINOL-BINDING PROTEINS, PLASMA; RISK FACTORS; SOLUTE CARRIER FAMILY 12, MEMBER 3; VASCULAR REMODELING; VASODILATION;

EID: 84900823253     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12270     Document Type: Article

References (31)

1. Waki H, Tontonoz P. Endocrine functions of adipose tissue. Annu Rev Pathol 2007;2:31-56.
2. Yang Q, Graham TE, Mody N, Preitner F, Peroni OD, Zabolotny JM et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 2005;436:356-62.
3. Quadro L, Blaner WS, Salchow DJ, Vogel S, Piantedosi R, Gouras P et al. Impaired retinal function and vitamin A availability in mice lacking retinol-binding protein. EMBO J 1999;18:4633-44.
4. Tönjes A, Fasshauer M, Kratzsch J, Stumvoll M, Blüher M. Adipokine pattern in subjects with impaired fasting glucose and impaired glucose tolerance in comparison to normal glucose tolerance and diabetes. PLoS ONE 2010;5:e13911.
5. Takebayashi K, Suetsugu M, Wakabayashi S, Aso Y, Inukai T. Retinol binding protein-4 levels and clinical features of type 2 diabetes patients. J Clin Endocrinol Metab 2007;92:2712-9.
6. Bobbert T, Raila J, Schwarz F, Mai K, Henze A, Pfeiffer AF et al. Relation between retinol, retinol-binding protein 4, transthyretin and carotid intima media thickness. Atherosclerosis 2010;213:549-51.
7. Takebayashi K, Sohma R, Aso Y, Inukai T. Effects of retinol binding protein-4 on vascular endothelial cells. Biochem Biophys Res Commun 2011;408:58-64.
8. Cubedo J, Padró T, Cinca J, Mata P, Alonso R, Badimon L. RBP4 levels and susceptibility to ischemic events in men. Eur J Clin Invest 2013;44:266-75.
9. Naesens M, Steels P, Verberckmoes R, Vanrenterghem Y, Kuypers D. Bartter's and Gitelman's Syndromes: from gene to clinic. Nephron Physiol 2004;96:65-78.
10. Calò LA. Vascular tone control in humans: insights from studies in Bartter's/Gitelman's syndromes. Kidney Int 2006;69:963-6.
11. Calò LA, Pessina AC. RhoA/Rho-kinase pathway: much more than just a modulation of vascular tone. Evidence from studies in humans. J Hypertens 2007;25:259-64.
12. Calò LA, Schiavo S, Davis PA, Pagnin E, Mormino P, D'Angelo A et al. Angiotensin II signaling via type 2 receptors in a human model of vascular hyporeactivity: implications for hypertension. J Hypertens 2010;28:111-8.
13. Calò LA, Pagnin E, Davis PA, Sartori M, Semplicini A. Oxidative stress related factors in Bartter's and Gitelman's syndromes: relevance for angiotensin II signalling. Nephrol Dial Transplant 2003;18:1518-25.
14. Calò L, Sartore G, Bassi A, Basso S, Bertocco R, Marin S et al. Reduced susceptibility of low density lipoprotein to oxidation in patients with overproduction of nitric oxide (Bartter's and Gitelman's syndrome). J Hypertens 1998;16:1001-8.
15. Calò LA, Puato M, Schiavo S, Zanardo M, Tirrito C, Pagnin E et al. Absence of vascular remodelling in a high angiotensin-II state (Bartter's and Gitelman's syndromes): implications for angiotensin II signalling pathways. Nephrol Dial Transplant 2008;23:2804-9.
16. Calò LA, Montisci R, Scognamiglio R, Davis PA, Pagnin E, Schiavo S et al. High angiotensin II state without cardiac remodeling (Bartter's and Gitelman's syndromes). Are angiotensin II type 2 receptors involved? J Endocrinol Invest 2009;32:832-6.
17. Davis PA, Pagnin E, Semplicini A, Avogaro A, Calo' LA. Insulin signaling, glucose metabolism and the angiotensin II signaling system Studies in Bartter's/Gitelman's syndromes. Diabetes Care 2006;29:469-71.
18. Calò L, Cantaro S, Piccoli A, Favaro S, Bonfante L, Borsatti A. Full pattern of urinary prostaglandins in Bartter's syndrome. Nephron 1990;56:451-2.
19. Calò LA, Davis PA, Pagnin E, Dal Maso L, Caielli P, Rossi GP. Calcitonin gene-related peptide, heme oxygenase-1, endothelial progenitor cells and nitric oxide-dependent vasodilation relationships in a human model of angiotensin II type-1 receptor antagonism. J Hypertens 2012;30:1406-13.
20. Datla SR, Dusting GJ, Mori TA, Taylor CJ, Croft KD, Jiang F. Induction of heme oxygenase-1 in vivo suppresses NADPH oxidase derived oxidative stress. Hypertension 2007;50:636-42.
21. Kim YM, Pae HO, Park JE, Lee YC, Woo JM, Kim NH et al. Heme oxygenase in the regulation of vascular biology: from molecular mechanisms to therapeutic opportunities. Antioxid Redox Signal 2010;14:137-67.
22. Martin D, Rojo AI, Salinas M, Diaz R, Gallardo G, Alam J et al. Regulation of heme oxygenase-1 expression through the phosphatidylinositol 3-kinase/Akt pathway and the Nrf2 transcription factor in response to the antioxidant phytochemical carnosol. J Biol Chem 2004;279:8919-29.
23. Graham TE, Yang Q, Blüher M, Hammarstedt A, Ciaraldi TP, Henry RR et al. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med 2006;354:2552-63.
24. von Eynatten M, Lepper PM, Liu D, Lang K, Baumann M, Nawroth PP et al. Retinol-binding protein 4 is associated with components of the metabolic syndrome, but not with insulin resistance, in men with type 2 diabetes or coronary artery disease. Diabetologia 2007;50:1930-7.
25. Pala L, Monami M, Ciani S, Dicembrini I, Pasqua A, Pezzatini A et al. Adipokines as possible new predictors of cardiovascular diseases: a case control study. J Nutr Metab 2012;2012:253428.
26. Alkharfy KM, Al-Daghri NM, Vanhoutte PM, Krishnaswamy S, Xu A. Serum retinol-binding protein 4 as a marker for cardiovascular disease in women. PLoS ONE 2012;7:e48612.
27. Calò LA, Pagnin E, Davis PA, Sartori M, Ceolotto G, Pessina AC et al. Increased expression of regulator of G protein signaling-2 (RGS-2) in Bartter's/Gitelman's syndrome. A role in the control of vascular tone and implication for hypertension. J Clin Endocrinol Metab 2004;89:4153-7.
28. Calò LA, Pagnin E, Ceolotto G, Davis PA, Schiavo S, Papparella I et al. Silencing regulator of G protein signaling-2 (RGS-2) increases angiotensin II signaling: insights into hypertension from findings in Bartter's/Gitelman's syndromes. J Hypertens 2008;26:938-45.
29. Pagnin E, Davis PA, Sartori M, Semplicini A, Pessina AC, Calò LA. Rho kinase and PAI-1 in Bartter's/Gitelman's syndromes: relationship to angiotensin II signaling. J Hypertens 2004;22:1963-9.
30. Calò LA, Davis PA, Pagnin E, Dal Maso L, Maiolino G, M Seccia T et al. Increased level of p63RhoGEF and RhoA/Rho kinase activity in hypertensive patients. J Hypertens 2014;32:331-8.
31. Wolfrum S, Dendorfer A, Rikitake Y, Stalker TJ, Gong Y, Scalia R et al. Inhibition of Rhokinase leads to rapid activation of phosphatidylinositol 3 kinase/protein kinase Akt and cardiovascular protection. Arterioscler Thromb Vasc Biol 2004;24:1842-7.